Sailu Challapalli named as Chief Product Officer and Hylton Kalvaria named as Chief Commercial Officer
Mendel, the leading clinical artificial intelligence and natural language processing platform, today announced the expansion of its leadership team with two key C-suite hires: Sailu Challapalli as Chief Product Officer and Hylton Kalvaria as Chief Commercial Officer. The company continues to source exceptional individuals from the strongest organizations in healthcare and technology. Challapalli and Kalvaria bring significant experience to the Mendel team to aid the company’s strategic expansion.
“We’re excited to welcome Sailu and Hylton to Mendel’s executive leadership team,” said Karim Galil, co-founder and CEO of Mendel. “Sailu and Hylton hail from some of the most important and disruptive real world evidence companies in the world. I’m thrilled to have them lead and grow our product, customer and commercial organizations.”
Challapalli has nearly two decades of experience working in healthcare consulting, academic medical centers, and healthcare technology companies. Most recently, she served as the VP of Product Management at Flatiron Health, where she helped to scale its custom real world evidence data & analytic product line. Prior to Flatiron, Challapalli held various roles at Kyruus, in McKinsey & Company’s Healthcare Systems & Services practice, and at Columbia University Medical Center focused on leveraging healthcare technologies and data to improve patient access and quality of care.
Kalvaria joins Mendel from Verana Health where he served as Chief Business Officer. At Verana, he built a world class commercial and delivery function including sales, marketing, partnerships and quantitative science teams. Kalvaria previously held a variety of roles at Flatiron Health and Genentech, both focused on the development and usage of high quality real world evidence for use across the healthcare industry.
The healthcare industry faces immense challenges in parsing unstructured medical data that is highly valuable, but also extremely difficult and expensive to access. Mendel’s solution unlocks 80% of the world’s clinical data by leveraging contextual understanding to transform unstructured electronic medical record (EMR) data and clinical literature into comprehensive and compliant analytics-ready data. It abstracts data 27,000 times faster than the primarily manual methods most frequently used in clinical settings, and its output is reviewed and validated by a team of clinical experts to guarantee research-grade output.
Mendel closed a $40 million Series B funding round in April from Oak HC/FT with participation from existing investor DCM. The company is poised for significant market expansion in 2022 and will be expanding headcount across offices in San Francisco Bay Area, New York City and Cairo, Egypt.
For more information about Mendel visit Mendel.ai, and to see open positions visit Mendel.ai/careers.